Alemtuzumab for the treatment of multiple sclerosis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Future Neurology

• Publication date

  2010-03-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/FNL.09.81
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

  2010cited by this paper
• A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

  2010cited by this paper
• A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

  2010cited by this paper
• Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model

  2009cited by this paper
• Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis

  2009cited by this paper
• IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

  2009cited by this paper
• Melanoma following treatment with alemtuzumab for multiple sclerosis

  2009cited by this paper
• Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

  2008cited by this paper
• Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

  2008cited by this paper
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

  2008cited by this paper
• Risk alleles for multiple sclerosis identified by a genomewide study.

  2007cited by this paper
• Oral fingolimod (FTY720) for relapsing multiple sclerosis.

  2006cited by this paper
• Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II‐defined cohort of patients with progressive multiple sclerosis: results of a 24‐month double‐blind placebo‐controlled clinical trial and 5 years of follow‐up treatment

  2006cited by this paper
• A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

  2006cited by this paper
• Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.

  2005cited by this paper
• Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis

  2005cited by this paper
• Treatment with laquinimod reduces development of active MRI lesions in relapsing MS

  2005cited by this paper
• Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

  2005cited by this paper
• The window of therapeutic opportunity in multiple sclerosis

  2005cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

  2004cited by this paper
• Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications.

  2003cited by this paper
• The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis

  2003cited by this paper
• Relapse of Graves' disease after successful allogeneic bone marrow transplantation

  2001cited by this paper
• Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis.

  2000cited by this paper
• Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey.

  2000cited by this paper
• A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations

  2000cited by this paper
• Autoimmune diseases in families of French patients with multiple sclerosis

  2000cited by this paper
• A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease

  1999cited by this paper
• Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.

  1999cited by this paper
• The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Delayed occurrence of Graves' disease after immune restoration with HAART

  1998cited by this paper
• Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.

  1997cited by this paper
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996cited by this paper
• Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

  1996cited by this paper
• Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

  1995cited by this paper
• Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis.

  1994cited by this paper
• A major mRNA of the human epididymal principal cells, HE5, encodes the leucocyte differentiation CDw52 antigen peptide backbone

  1993cited by this paper
• Epidemiologic evidence for multiple sclerosis as an infection

  1993cited by this paper
• Overview of azathioprine treatment in multiple sclerosis.

  1991cited by this paper
• Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double‐blinded, placebo‐controlled clinical trial

  1990cited by this paper
• Affective disorders in multiple sclerosis. Review and recommendations for clinical research.

  1990cited by this paper
• Cyclosporine versus azathioprine in the long‐term treatment of multiple sclerosis—results of the german multicenter study

  1988cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper

• Graves’ disease induced by Alemtuzumab in relapsing–remitting multiple sclerosis patients: an observational study in a reference center

  2022cites this paper
• Analysis of herpesvirus infection and genome single nucleotide polymorphism risk factors in multiple sclerosis, Volga federal district, Russia

  2022cites this paper
• A review of possible therapies for multiple sclerosis

  2021cites this paper
• Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis

  2021cites this paper
• Multiple Sclerosis

  2021cites this paper
• Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis

  2020cites this paper
• Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis

  2020cites this paper
• Long-term drug treatment in multiple sclerosis: safety success and concerns

  2020cites this paper
• Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?

  2018cites this paper
• A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes

  2018cites this paper